Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho

Core Insights - Avant Technologies Inc. and Austrianova have launched a joint venture named Klothonova LLC, focusing on the Klotho development program aimed at creating cell-based therapies for age-related diseases and promoting longevity [1][4] - The Klotho protein is recognized for its anti-aging properties, and the global market for cell-based therapies is projected to reach $44 billion [4][5] Research and Development - The initial phase of the program has successfully generated genetically modified human cells that overproduce the Klotho protein, demonstrating the feasibility of using encapsulated cells for continuous production [2][3] - Austrianova is preparing for the next stage by ensuring compliance with GMP standards and conducting necessary documentation for preclinical and clinical studies [3][4] Joint Venture Details - Klothonova is a Nevada-based entity equally owned by Avant and Austrianova's affiliate, SGAustria Pte. Ltd., established through a joint venture agreement signed in September 2025 [4] - The collaboration leverages Austrianova's cell encapsulation technology and Avant's innovative vision, positioning the joint venture for success in the biotechnology sector [4]